CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has received its first two orders through its own sales organization in the US. The company's analyzers, CellaVision® DM96, will be installed in one of the largest public hospitals in the US and in a regional reference laboratory. The orders include four CellaVision® DM96 analyzers and annual licenses for CellaVision® Remote Review Software and CellaVision® Competency Software. These software products allow remote access, collaboration, education and proficiency testing."It is very exciting to see the first results from our investment in our US sales organization over the past year," says Yvonne Mårtensson, CEO of CellaVision. "These first orders indicate that CellaVision has successfully established its own sales channel in the US, while we are simultaneously continuing our well-established partnership with Sysmex." Using CellaVision's technology for automated digital cell morphology, laboratories can reduce the total labor spent performing manual blood cell differentials and generate reliable and more standardized analyses. The analyzer CellaVision® DM96 and the CellaVision® Remote Review Software increase productivity, collaboration between personnel and laboratories, and also provide staffing flexibility. In addition, CellaVision® Competency Software is an effective educational tool. Since early 2008, CellaVision's products have been sold in the US by the company's own subsidiary, CellaVision Inc., in parallel with a distributor, Sysmex America. The US is one of CellaVision's most important markets. In 2007, USA and Canada counted for approximately 40 percent of CellaVision's total turnover. For more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 46-286 44 00. E-mail: yvonne.martensson@cellavision.com About CellaVision CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy. The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com. CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.